Posted on 16/10/2009 in Pharmaceutical Company Product News Shire has announced that it has settled all pending litigation with Sandoz in connection with the latter firm's abbreviated new drug application and its attempt to market generic versions of Shire's Adderall XR (mixed amphetamine salts).
Sandoz has agreed to confirm that its proposed generic products infringe Shire's 819 and 300 patents and that the two patents are enforceable and valid.
The settlement for the product, which is used for the treatment of attention deficit hyperactivity disorder, provides Sandoz with a license to market it own generic versions of Adderall XR, upon the approval of its own generic products.
Sandoz will then pay Shire royalties from the sales of these products.
Currently, Impax Pharmaceuticals and Barr Laboratories remain the only authorised generic suppliers of Adderall XR.
This week, Shire announced that a trial conducted into its chronic kidney disease treatment Fosrenol found that the drug may offer greater serum phosphorus reduction in those suffering from the condition.
Other news stories from 16/10/2009
Read more in the Zenopa News Archive
How this news is generated
|
